Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy

Expert Opinion on Biological Therapy
Marc-Michael Zaruba, Wolfgang-Michael Franz

Abstract

Ischemic disorders are the leading cause of mortality worldwide, current therapies only delay progression of the disease. Data suggest a role of the SDF-1-CXCR4 axis in attenuation of ischemic disorders. We discuss the importance of SDF-1-CXCR4 interactions during development and postnatal mobilization and migration of stem cells. We focus on the role of the SDF-1-CXCR4 axis in stem-cell-based applications for attenuation of ischemic cardiomyopathy. During development the SDF-1-CXCR4 axis plays a critical role in gradient-guided cell movements. In adults, the SDF-1-CXCR4 axis is involved in retention and mobilization of stem cells. Since SDF-1 is upregulated during hypoxic tissue damage, strategies to augment or stabilize SDF-1 have been utilized to target blood-derived stem cells to ischemic tissue. We exploited this concept by preventing SDF-1 degradation with dipeptidylpeptidaseIV (DPPIV) inhibition and mobilization of stem cells by G-CSF after acute myocardial infarction. This targeted CD34(+)CXCR4(+) cells to ischemic heart and attenuated ischemic cardiomyopathy. The SDF-1-CXCR4 axis plays a role in stem cell homing during embryogenesis and adulthood especially after ischemia. Preserving functional SDF-1 by DPPIV inhibitio...Continue Reading

References

Sep 10, 1999·Developmental Biology·K E McGrathJ Palis
Apr 5, 2001·Nature·D OrlicP Anversa
Sep 4, 2001·International Journal of Hematology·H E Broxmeyer
Feb 28, 2002·The Journal of Biological Chemistry·Agustín Valenzuela-FernándezFernando Arenzana-Seisdedos
Dec 10, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kent W ChristophersonHal E Broxmeyer
Apr 10, 2003·Proceedings of the National Academy of Sciences of the United States of America·Toshiaki AraTakashi Nagasawa
Sep 25, 2003·Cell·Antonio P BeltramiPiero Anversa
Jul 6, 2004·Nature Medicine·Daniel J CeradiniGeoffrey C Gurtner
Aug 18, 2004·Science·Kent W ChristophersonHal E Broxmeyer
Apr 20, 2005·The Journal of Experimental Medicine·Hal E BroxmeyerEdward F Srour
May 12, 2005·Trends in Cardiovascular Medicine·Daniel J Ceradini, Geoffrey C Gurtner
Sep 9, 2005·The New England Journal of Medicine·Nikos WernerGeorg Nickenig
Mar 2, 2006·JAMA : the Journal of the American Medical Association·Dietlind ZohlnhöferUNKNOWN REVIVAL-2 Investigators
Jul 26, 2006·Experimental Hematology·Ingrid G Winkler, Jean-Pierre Lévesque

❮ Previous
Next ❯

Citations

Jun 4, 2011·Cardiovascular Drugs and Therapy·Drew KuraitisErik J Suuronen
Nov 1, 2011·The Journal of Biological Chemistry·Vikas SainiMatthias Majetschak
Sep 10, 2010·Human Gene Therapy·Conrad P HodgkinsonVictor J Dzau
Sep 21, 2010·Cardiovascular Research·Winston ShimPhilip Wong
Mar 28, 2012·Cardiovascular Research·Chiara CencioniMonica Napolitano
Nov 23, 2011·Journal of Burn Care & Research : Official Publication of the American Burn Association·Todd A BakerMatthias Majetschak
Jun 14, 2013·Journal of Translational Medicine·Thomas E IchimAmit N Patel
Mar 5, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Shinya Minatoguchi
May 29, 2012·Molecular Medicine·Harold H BachMatthias Majetschak
Aug 7, 2013·Basic Research in Cardiology·Sean M DavidsonDerek M Yellon
Jan 12, 2011·Expert Opinion on Biological Therapy·Ting Ting Lau, Dong-An Wang
Oct 7, 2015·Scandinavian Cardiovascular Journal : SCJ·Dana LiNadia L Landex
Nov 19, 2013·International Journal of Cardiology·Marc-Michael ZarubaWolfgang-Michael Franz
Feb 7, 2014·Canadian Journal of Diabetes·Andrew AdvaniKim A Connelly
Apr 8, 2014·Pharmacology & Therapeutics·Daniel I BromageDerek M Yellon
Jan 23, 2016·Thrombosis and Haemostasis·Birgit SteppichUNKNOWN Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) Study Investigators
Jul 12, 2011·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Jacquelyn Choate, Edward L Snyder
Jun 15, 2011·Vascular Pharmacology·Gian Paolo Fadini, Angelo Avogaro
Oct 21, 2015·Cardiovascular Drugs and Therapy·A MalikD M Yellon
Jul 26, 2012·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Fabio TucheRené Schramm
May 2, 2012·Annals of the New York Academy of Sciences·Liza K Phillips, Johannes B Prins
Feb 15, 2012·Brain Research·Shenghui LiJianning Zhang
Oct 7, 2015·Frontiers in Immunology·Jixin Zhong, Sanjay Rajagopalan
Apr 9, 2016·Journal of Cardiovascular Translational Research·Bong-Sung KimChristian Stoppe
Mar 11, 2015·Journal of Cellular and Molecular Medicine·Bruno C HuberStefan Brunner
Nov 26, 2011·Journal of the American College of Cardiology·Nikolaos G Frangogiannis
Jul 3, 2016·Heart Failure Clinics·Amanda J Favreau-LessardDouglas B Sawyer
Dec 16, 2016·International Endodontic Journal·Y SueyamaT Okiji

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Actin, Myosin & Cell Movement

Contractile forces generated by the actin-myosin cytoskeleton are critical for morphogenesis, but the cellular and molecular mechanisms of contraction have been elusive for many cell shape changes and movements. Here is the latest research on the roles of actin and myosin in cell movement.

Cardiac Regeneration

Cardiac regeneration enables the repair of irreversibly damaged heart tissue using cutting-edge science, including stem cell and cell-free therapy. Discover the latest research on cardiac regeneration here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.